Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2025 08:13 ET | Source: Yamo Pharmaceuticals

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

Yamo Pharma's Phase 2 data at INSAR 2025 show L1-79 delivers statistically significant and clinically meaningful improvements in core autism symptoms.